Thomas Cannell, Sesen Bio CEO
Sesen takes next step after investor attack, calls for shareholder vote to approve merger
Two and a half weeks after Sesen Bio pushed back against an investor group opposing a merger with Carisma Therapeutics, the biotech is moving forward …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.